FDA-Cleared Parameters Aid in the Diagnosis of Infectious and Inflammatory

Diseases and in Monitoring Iron Deficiency

MUNDELEIN, Ill., Oct. 30 /PRNewswire/ -- Sysmex America, Inc. today
announced that the United States Food and Drug Administration (FDA) has
cleared Sysmex's Immature Granulocyte (IG) parameter and Reticulocyte
Hemoglobin Equivalent (RET-He) parameter for use on the company's
XT-Series(TM) Automated Hematology Analyzers for low to mid-volume
laboratories, said John Kershaw, President, Sysmex America, Inc. This
announcement follows the company's earlier clearances of the same
parameters for the Sysmex XE-Series(TM) Automated Hematology Analyzers.
Now, clinical laboratories of any size can potentially benefit from
enhanced diagnostic information, workflow process improvement, and greater
cost-effectiveness, added Kershaw. The IG parameter is now available on
both the XT-2000i and the XT-1800i, and the RET-He is available on the
XT-2000i Automated Hematology Analyzers. Sysmex is the only company able to
provide both of these FDA-cleared parameters.

The RET-He parameter is a sensitive measurement of iron available for
red cell production. Functional iron available for incorporation into the
red cell hemoglobin can be monitored via the RET-He, thus assisting
physicians monitoring disease states where iron deficiency is often seen.
Less than normal hemoglobin content in reticulocytes, immature red blood
cells (RBCs), is an indication of inadequate iron supply relative to
demand. The amount of hemoglobin in these reticulocytes also corresponds to
the amount of hemoglobin in mature RBCs. The RET-He parameter provides a
direct measurement of the mean reticulocyte hemoglobin content. Therefore,
it is a useful parameter for assisting physicians with early diagnosis of
iron deficiency (iron restricted erythropoiesis), and for optimizing iron
therapy.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation
(Kobe, Japan), is a world leader in clinical laboratory systemization and
solutions, including clinical diagnostics, automation and information
systems. Serving customers for over 40 years, Sysmex focuses on extending
the boundaries of diagnostic science while providing the management
information tools that make a real difference in clinical and operational
results for people worldwide. For more information about Sysmex, please
visit http://www.sysmex.com/usa.

(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...

(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...

(Date:6/14/2017)... 15, 2017 IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...